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Abstract
Introduction: Glycoprotein IIb/IIIa inhibitors have a key role in the treatment of patients with acute
coronary syndromes undergoing percutaneous interventions. Although, an increased risk of bleeding
complications is well recognized, its association with diffuse alveolar hemorrhage is much less
recognized. Previous authors have suggested that the incidence of glycoprotein IIb/IIIa inhibitor
associated diffuse alveolar hemorrhage has been significantly underestimated due to under reporting.
Case presentations: In order to help better determine the incidence of GP IIb/IIIa inhibitor
associated DAH, a retrospective review of medical records was conducted over a 1 year period at a
single high volume medical hospital. The medical records of all patients diagnosed with diffuse alveolar
hemorrhage were evaluated for treatment with a GP IIb/IIIa inhibitor within 48 hours of its diagnosis.
Each patient meeting the inclusion and exclusion criteria were included in the case series. This
number was compared with the total number of patients receiving a GP IIb/IIIa inhibitor during the
same time period and an incidence of the complication was calculated.
292 patients received either abciximab or eptifibatide during the one year review period and two
patients were diagnosed with diffuse alveolar hemorrhage confirmed by serial bronchiolar lavage for
an incidence of 0.68%. Of the total 292 patients receiving GP IIb/IIIa inhibitors, 172 patients received
abciximab with one occurrence of diffuse alveolar hemorrhage for an incidence of 0.58% while 120
patients received eptifibatide with one occurrence for an incidence of 0.83%. Both patients developed
significant morbidity as a result of the complication and 1 of the 2 patients died as a complication of
the disease.
Conclusions: Our findings support the claim that the incidence of GP IIb/IIIa induced diffuse alveolar
hemorrhage is substantially higher than initially suggested by drug manufacturer studies. Although
these drugs have proven mortality benefits, its association with diffuse alveolar hemorrhage is likely
under-recognized leading to significant under-reporting. The best way to more accurately determine
the true incidence of this complication and decrease its morbidity and mortality is to increase
awareness as well as include diffuse alveolar hemorrhage as a serious complication in product labeling.
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Glycoprotein IIb/IIIa (GP IIb/IIIa) inhibitors are potent
antiplatelet agents with proven benefits in the setting
of high-risk percutaneous coronary interventions (PCI).
Abciximab (ReoPro) is a fab fragment immunoglobulin
that binds to platelet glycoprotein IIb/IIIa receptors
preventing platelet aggregation and thrombus forma-
tion [1]. Likewise, eptifibatide (Integrilin), is a cyclic
heptapeptide that selectively binds to the glycoprotein
IIb/IIIa receptor with similar effects on platelet binding.
Both have been proven to have short and long-term
benefits in clinical studies [1,4]. In a meta-analysis of
the effectiveness and safety of GP IIb/IIIa receptor
blockers used in PCI, Brown et al showed that
treatment with eptifibatide was not associated with a
significant increase in risk of major bleeding. However,
a more recent case series suggested that this complica-
tion is likely significantly underestimated partially due
to the fact that no GP IIb/IIIa receptor blockers list
pulmonary hemorrhage as associated complications of
their use [2].
This retrospective analysis was initiated in order to better
determine the incidence of GP IIb/IIIa associated DAH. We
also sought to identify risk factors which might increase a
patients risk of developing DAH.
Case presentations
Methods
A retrospective review of medical records was conducted
at the University of Toledo Medical Center in Toledo, OH,
a level 1 trauma center with 3 high volume cardiac
catheterization suites. All patients that met each of the
inclusion and exclusion criteria between July 2006 and
2007 were included in the study.
The numbers of patients receiving at least one dose of GP
IIb/IIIa inhibitor were identified through a computer
search of the hospital pharmacy’s dispensing records
during the designated review period.
Patients diagnosed with diffuse alveolar hemorrhage were
identified through a computer search of the hospitals
database between July 2006 and June 2007. Each chart
was then reviewed using the following inclusion and
exclusion criteria.
Inclusion Criteria
1. New diagnosis of DAH confirmed by serial bronchoal-
veolar lavages.
2. Treatment with any Glycoprotein IIb/IIIa inhibitor
within 7 days of the diagnosis of DAH.
Exclusion Criteria
1. Treatment with any drugs known to be associated with
DAH within the previous 10 days other than a GP IIb/IIIa
inhibitor.
2. Diagnosis of Wegener’s granulomatosis, Goodpasture’s
syndrome, idiopathic pulmonary hemosiderosis, collagen
vascular disease or microscopic polyangiitis.
Follow-up: All patients with DAH were evaluated by both
a Cardiologist and a Pulmonary Critical Care Specialist on
a daily basis throughout their hospitalization.
Results
292 patients received either abciximab or eptifibatide
during the one year review period and revealed two
patients diagnosed with diffuse alveolar hemorrhage
confirmed by serial bronchiolar lavage for an incidence
of 0.68%. Of the total 292 patients receiving GP IIb/IIIa
inhibitors, 172 patients received abciximab with one
occurrence of diffuse alveolar hemorrhage for an incidence
of 0.58% while 120 patients received eptifibatide with one
occurrence for an incidence of 0.83%. Both patients
developed significant morbidity as a result of the
complication and 1 of the 2 patients died as a complica-
tion of the disease.
Case report 1
A 72 year old white female was transferred to the
emergency room by life-flight complaining of left sided
chest pain. Her past medical history was significant for
hypertension, hypothyroidism and hyperlipidaemia and
the patient had no prior history of smoking, cardiac
disease, or lung disease. The patients blood pressure at
presentation was 153/83, pulse 68 and respirations 20 per
minute. The patient denied any significant shortness of
breath, but her presenting chest X-ray (CXR) showed mild
bilateral alveolar infiltrates consistent with mild conges-
tive heart failure (Figure 1) and electrocardiography (ECG)
showing anterior ST elevations consistent with an acute
myocardial infarction. Laboratory evaluation included a
complete blood count, electrolytes, and coagulation
profile which were all within normal limits. The patient
was treated with aspirin, intravenous nitro-glycerine,
morphine and heparin by weight based protocol. Beta
blockers were held secondary to a mild hypotension into
the low 100’s after administration of morphine and IV
nitro-glycerine. Within 45 minutes of arrival, the patient
was taken emergently to the cardiac catheterization
laboratory for primary percutaneous revascularization.
Her angiogram revealed a proximal 99% stenosis of the
left anterior descending artery which was treated with
balloon angioplasty and stent placement. This resulted in
a complete reduction of the stenosis with corresponding
TIMI-3 flow in the affected artery. However, before
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bolus of abciximab, followed by continuous intravenous
infusion at 0.125 mcg/kg/min for 12 hours. Due to the
patients’ mild to moderate hypotension, she also under-
went right heart catheterization which showed a right
atrial pressure of 10, right ventricle pressure of 35/8-10,
pulmonary artery pressure of 35/25, pulmonary capillary
wedge pressure of 25, cardiac output 4.18 litres/min and
cardiac index of 2.21 litres/min/m
2. Based on these
findings the decision to place a temporary intra-aortic
balloon pump was made.
Approximately 30 minutes following the procedure, the
patient developed acute shortness of breath with pending
respiratory failure requiring emergent oral intubation.
Prior to intubation, the anaesthesiologist reported obser-
ving bright red blood within the posterior oropharynx, as
well as some blood within the endotracheal tube after its
Figure 1. CXR findings in GP IIb/IIIa induced DAH. (A & B) Anteroposterior view of chest x-ray at presentation.
(C) Anteroposterior view of chest x-ray seven days later. (D) Anteroposterior view of chest x-ray day later.
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showed moderate to severe bilateral alveolar infiltrates
which were a marked change from her admission CXR
(Figure 1A & 1C). These findings were attributed to acute
cardiogenic pulmonary edema and was therefore started
on intravenous furosemide and continued on intra-aortic
balloon pump support. However, over the first 12 hours of
the patient’s admission, she was noted to have a 3.2 gram
drop in haemoglobin of an unknown etiology. This lead to
the transfusion of two units of packed red blood cells.
However, although the patient’s hemodynamic status
improved allowing the discontinuation of the balloon
pump and heparin, over the next 72 hours the patient
developed diffuse alveolar infiltrates with worsening
hypoxia. Given this clinical picture, the diagnosis of
DAH was suspected and the patient underwent broncho-
scopy. This showed dark blood throughout the bronchial
tree with increasing hemorrhagic return on serial bronch-
iolar lavage confirming the diagnosis. In spite of intensive
supportive care over two additional weeks, the patient
condition continued to deteriorate and she died on
hospital day 21.
Case report 2
A 82-year-old man with the diagnosis of unstable angina
was transferred for possible PCI. His past medical history
included hypertension, hyperlipidemia, chronic renal
insufficiency (baseline creatinine 2 mg/dl), and previous
myocardial infarction with five vessel CABG for coronary
artery disease 10 years ago. He did have a remote smoking
history of four years but quit 65 years ago and had no
known history of lung disease.
Upon arrival to our facility, he was pain free and his blood
pressure was 120/75 mmHg with heart rate of 74 beats per
minute. ECG showed normal sinus rhythm, left axis
deviation, and ST segment depression in the inferior leads.
The patients’ prothrombin time was 14 seconds with a
corresponding INR of 1.2 and a normal platelet count.
CXR did not reveal any infiltrates or other acute processes
(Figure 1B).
The patient was treated with full dose aspirin, started on
heparin by standard weight based protocol, and taken to
the cardiac catheterization laboratory for coronary angio-
graphy. The coronary angiogram showed severe native
three vessel disease, widely patent RIMA and LIMA, and
80% focal stenosis in the mid portion of the patients
saphenous vein graft to the obtuse marginal branch of the
left circumflex artery. These findings correlated with the
patients ECG findings and therefore he underwent
percutaneous coronary intervention of his saphenous
vein graft. A bolus of 180 mcg/kg of intravenous
eptifibatide was given followed by a continuous intrave-
nous infusion at 1 mcg/kg/min for 18 hours. Balloon
angioplasty and stenting was performed using standard
technique and reduced the stenosis to 0% restoring TIMI-3
coronary flow to the vessel. Following the procedure, the
patient was transferred to the coronary care unit in stable
condition.
Four hours following the procedure the patient developed
severe dyspnea and hypoxemia. Electrocardiography
revealed sinus tachycardia and arterial blood gas measure-
ments on 100% non re-breather mask showed a pH of
7.44, Po2 of 50 mmHg a Pco2 of 32 mmHg, and oxygen
saturation of 85%. Chest examination revealed diffuse
rales over both the lung fields, and bed side CXR revealed
bilateral diffuse alveolar infiltrates. (Figure 1D).
Based on the clinical picture, the patient was diagnosed
with respiratory insufficiency secondary to acute cardio-
genic pulmonary edema related to his recent myocardial
infarction and was treated with intravenous diuretics for
48 hours. During this time, the patients clinically picture
did not improve leading to a right heart catheterization
revealing a right atrial pressure of 6 mmHg, a pulmonary
capillary wedge pressure of 9 mmHg, cardiac output of
5.45 litres/min, and a cardiac index of 2.74 litres/min/
sqm. These findings were suggestive of non-cardiogenic
pulmonary edema and resulted in an alternative workup
for the patients’ unexplained respiratory insufficiency
and pulmonary infiltrates. The possibility of pulmonary
embolus was first investigated, but negative lower
extremity Doppler’s and a low probability ventilation
perfusion scan made this diagnosis unlikely.
High resolution chest computed tomography was per-
formed without contrast and showed bilateral ground
glass opacities with interstitial infiltrates involving the
upper and lower lobes consistent with pulmonary edema
(Figure 2).
When the patients’ haemoglobin subsequently fell two
gram over 24 hours, the diagnosis of DAH was suspected.
The patient underwent bronchoscopy which revealed
diffused blood throughout the bronchial tree with
increased hemorrhagic return on serial bronchiolar lavages
confirming the diagnosis of DAH. Subsequently, the
patient was treated with methylprednisolone 125 mg
IV × 3 days followed by a 9 day taper. The patients
oxygenation steadily improved over the next 7 days and
the patient was eventually discharged from the hospital on
day 17 days with no further complications.
Discussion
Glycoprotein IIb/IIIa inhibitors are antiplatelet agents
currently recommended in the treatment of patients with
unstable angina and non ST-elevated myocardial infarc-
tions [3]. There efficacy is believed to be secondary to
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generation and fibrin formation associated with PCI.
However, despite these clear cardiovascular benefits, there
is a coexisting increase in the risk of bleeding complica-
tions. Increased bleeding complications are most com-
monly seen at vascular access sites, however, other
reported bleeding sites include intra-cranial, retroperito-
neal, urological and gastrointestinal sources [4].
Sitges and Villa were the first to report a case of pulmonary
hemorrhage after abciximab use in 1997, and more
recently Orford reported the first case of eptfibatide
associated alveolar hemorrhage in 2004 [5]. Since then,
there has been a scattered, but steadily growing number of
case reports detailing accounts of alveolar hemorrhage
associated with the use of all three GP IIb/IIIa inhibitors.
Early diagnosis of pulmonary hemorrhage can be extre-
mely challenging. This is because symptoms such as
hemoptysis, hypoxemia, and new chest radiological
infiltrates are often erroneously attributed to congestive
heart failure, acute respiratory distress syndrome, or
pulmonary embolism. The fact that hemoptysis can be
absent in as many as one-third of all cases of DAH further
complicates the diagnosis [6]. Misdiagnosis usually results
in inappropriate evaluation and treatment of suspected
heart failure, unnecessary use of antibiotics, or even
extended exposure to anticoagulation. Since the diagnosis
of DAH from any cause represents a medical emergency,
prompt diagnosis and removal of the inciting agent is of
utmost importance.
Recently Khanlou et al reported seven cases of pulmonary
hemorrhage associated with the use of abciximab and
suggested that the presence of underlying lung conditions,
such as chronic obstructive pulmonary disease, pulmonary
hypertension, high pulmonary-capillary wedge pressure,
and elevated left ventricular end diastolic pressure
(LVEDP) may be associated with an increased risk of
pulmonary hemorrhage [6]. In our case series, elevated
LVEDP and high pulmonary-capillary wedge pressures
were present and old age, chronic renal insufficiency, and
standard doses of heparin used in combination with GP
IIb/IIIa inhibitors may have increased the patient’s risk of
developing pulmonary hemorrhage. These cases are part of
a growing body of evidence that suggest the incidence
of GP IIb/IIIa induced pulmonary hemorrhage may be
greater than previously reported due to under-recognition
or misdiagnosis. Those researchers also suggested that
failure of GP IIb/IIIa inhibitor manufacturers to include
this complication in its product labeling likely contributes
to under diagnosis of this complication.
A recent large scale retrospective analysis of patients
receiving abciximab or eptifibatide reported that alveolar
hemorrhage was diagnosed in 11 of 5458 (0.2%) treated
patients compared to only one episode of alveolar
hemorrhage in the 4136 patients (0.025%) not receiving
GP IIb/IIIa inhibitors. Compared to control group,
patients treated with GP IIb/IIIa inhibitors had a
statistically significant increase in the risk of developing
alveolar hemorrhage.
Although there are no established guidelines for the
treatment of GP IIb/IIIa receptor inhibitor induced
alveolar hemorrhage, removal of the offending agent as
well as discontinuation of all forms of anticoagulation
as soon as possible remains the mainstay of treatment.
Figure 2. CT scan findings in DAH, Sagittal high resolution chest CT without contrast showing bilateral ground glass opacities
with interstitial septal thickening suggestive of acute interstitial process.
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hemorrhage has been shown to benefit from treatment
with corticosteroids, most other drug induced causes of
alveolar hemorrhage have not been shown to benefit
from its use. Therefore, the decision to use steroids in
GP IIb/IIIa inhibitor induced alveolar hemorrhage is
controversial and varies by clinician.
Although the patient in our second case received steroids
and subsequently improved, while the patient not treated
with steroids failed to recover; one should not prematurely
conclude that a correlation between these two things
exists. Although both developed DAH in association with
GP IIb/IIIa inhibitors, the differences between these two
cases were substantial. More likely, the adverse outcome in
the first case may simply be related to the fact that the
diagnosis was delayed over 72 hours longer than that of
the second patient (Table 1).
Conclusions
A high index of clinical suspicion for DAH is essential
whenever GP IIb/IIIa inhibitors are used. Respiratory
distress, worsening alveolar infiltrates, in addition to a
sudden fall in haemoglobin with or without hemoptysis,
should alert the physician to the possibility of pulmonary
hemorrhage. Diagnostic bronchoscopy should be consid-
ered early when the diagnosis is suspected because adverse
outcomes seem to correlate with delayed diagnosis and
treatment. Current treatment of DAH from any cause
includes discontinuation of offending agents, stopping all
anticoagulation as soon as possible, and careful considera-
tion of the potential risks and benefits of using intrave-
nous corticosteroids [3].
The diagnosis of DAH is a serious condition that is
associated with significant morbidity and mortality. Since
early diagnosis appears key to decreasing adverse out-
comes, we agree with the conclusions of Iskandar in
stating that diffuse alveolar hemorrhage is likely an under-
diagnosed complication of GP IIb/IIIa inhibitors and that
this complication should be added to the product
labelling of GP IIb/IIIa inhibitors as a potentially life
threatening adverse reactions.
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